Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price […]
Investment analysts at Robert W. Baird assumed coverage on shares of Coherus BioSciences (NASDAQ:CHRS – Get Free Report) in a note issued to investors on Friday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $11.00 price target on the biotechnology company’s stock. Several other brokerages have also weighed in on CHRS. Bank […]
Steel Peak Wealth Management LLC increased its position in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) by 100.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,000 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the quarter. Steel […]
– LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy.